In Vitro Equivalence Assessment Method for Atomization Characteristics of Budesonide Nasal Spray Products
Acta Poloniae Pharmaceutica - Drug Research · 03.03.2026 · 82 (5) · 717-730
DOI: 10.32383/appdr/217360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Poloniae Pharmaceutica - Drug Research, online erschienen am 03.03.2026. Verfasst von Langyi Niu und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In vitro testing is increasingly replacing systemic pharmacokinetic studies in assessing the equivalence of generic and reference locally acting nasal sprays. Establishing reliable in vitro methods and investigating factors that may affect equivalence tests is crucial. In this study, we evaluated the in vitro atomization characteristics of a self-prepared budesonide nasal spray (Formulation A) and a reference drug (Formulation B). A simple and efficient Python program was used to assess population bioequivalence, achieving a high level of automation with audit trail capabilities. The single actuation content, droplet size distribution, and plume geometry met the criteria for population bioequivalence (Hη
Zitieren
APA
Niu, L., Zhou, Y., Guo, N., Sun, C., & WEI, N. (2026). In Vitro Equivalence Assessment Method for Atomization Characteristics of Budesonide Nasal Spray Products. Acta Poloniae Pharmaceutica - Drug Research, 82(5), 717-730. https://doi.org/10.32383/appdr/217360
Vancouver
Niu L, Zhou Y, Guo N, Sun C, WEI N. In Vitro Equivalence Assessment Method for Atomization Characteristics of Budesonide Nasal Spray Products. Acta Poloniae Pharmaceutica - Drug Research. 2026;82(5):717-730. doi:10.32383/appdr/217360
BibTeX
@article{Niu2026,
author = {Niu, Langyi and Zhou, Ying and Guo, Ningzi and Sun, Chunmeng and WEI, Ningyi},
title = {In Vitro Equivalence Assessment Method for Atomization Characteristics of Budesonide Nasal Spray Products},
journal = {Acta Poloniae Pharmaceutica - Drug Research},
year = {2026},
volume = {82},
number = {5},
pages = {717--730},
doi = {10.32383/appdr/217360}
}
EUVIMED